Trust Co. of Vermont Sells 36,394 Shares of Pfizer Inc. $PFE

Key Points

• Trust Co. of Vermont reduced its stake in Pfizer by 12.9%, selling 36,394 shares and holding 246,091 shares valued at $5,965,000 by the end of the quarter.
• Analysts have updated their price targets for Pfizer, with Bank of America increasing its target to $28.00, while Citigroup raised theirs to $26.00, both rating it as "neutral."
• Pfizer reported $0.78 earnings per share for the last quarter, exceeding expectations and demonstrating a revenue increase of 10.3% year-over-year.

Trust Co. of Vermont lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 12.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 246,091 shares of the biopharmaceutical company's stock after selling 36,394 shares during the quarter. Trust Co. of Vermont's holdings in Pfizer were worth $5,965,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the 1st quarter worth $27,000. North Capital Inc. bought a new stake in shares of Pfizer during the 1st quarter worth $28,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer during the 1st quarter worth $28,000. Horizon Financial Services LLC bought a new stake in shares of Pfizer during the 1st quarter worth $35,000. Finally, WPG Advisers LLC acquired a new position in shares of Pfizer during the first quarter worth approximately $35,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on PFE shares. Bank of America upped their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a report on Sunday. Finally, Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $25.46 on Wednesday. The business's fifty day moving average price is $24.55 and its two-hundred day moving average price is $24.11. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The stock has a market capitalization of $144.75 billion, a price-to-earnings ratio of 13.54, a price-to-earnings-growth ratio of 0.77 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the prior year, the business posted $0.60 earnings per share. The business's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.